Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- 3 Groups Reconfirm Opposition to Deregulating Online Sale of OTC Drugs
July 4, 2011
- Mebiopharm to Be Listed on TOKYO AIM on July 15
July 4, 2011
- Largest No. of New Drugs Listed in FY2010 in the Past 15 Years: FPMAJ
July 4, 2011
- JPA Presents Its Opinions on OTC Drug Risk Reclassification to Korosho
July 4, 2011
- Combined Sales of 23 Japanese Drug Companies Reach ¥100 billion in China
July 4, 2011
- Nihon Chouzai to Invest ¥10 Bil. to Increase GE Production Capacity
July 4, 2011
- Anticancer Drug Market in Japan to Exceed ¥1 Tril. in 2019: Fuji-Keizai
July 4, 2011
- Pfizer Japan to Promote Established Products with Force of 1,000
July 4, 2011
- Drug Market for Metabolic Diseases to Grow to ¥430 Bil. in 2019: Fuji-Keizai
July 4, 2011
- MTPC Expects 8 Launches in FY2011
July 4, 2011
- Generics of Actos Listed from 18 Companies
July 4, 2011
- MTPC, JCRS to Integrate Their Plasma Fraction Products Business in April 2012
July 4, 2011
- Actos Generics Launched Despite Various Issues
July 4, 2011
- FUJIFILM, Mitsubishi Corp. Tie-up to Contract Manufacture Biopharmaceuticals
July 4, 2011
- Nihon Chouzai to Invest ¥10 Bil. to Increase GE Production Capacity
July 4, 2011
- Price Settlement Rate Up to 93.9% in March: Korosho
July 4, 2011
- FDA Approves Generics of Levofloxacin from 12 Companies
July 4, 2011
- Equa Ranked No. 1 Both in GP, HP Markets in April: RepTrack Survey
July 4, 2011
- Industry Submits Proposal to Freeze Prices of Essential Drugs
July 4, 2011
- Korosho Designates 5 Products including Dornase as Orphan Drugs
July 4, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…